
ePT--the Electronic Newsletter of Pharmaceutical Technology
SEC Loosens Revenue-Recognition Rules for Vaccine Stockpile Participants


ePT--the Electronic Newsletter of Pharmaceutical Technology
SEC Loosens Revenue-Recognition Rules for Vaccine Stockpile Participants

ePT--the Electronic Newsletter of Pharmaceutical Technology
FDA Warns Consumers Against Unapproved, Contaminated 'Miracle II Neutralizer'

To qualify and validate a pharmaceutical manufacturing facility, one must carefully review the facility design for compliance with good manufacturing practices and manage project scope definition, labor and cost estimating, and master-plan development.These activities, properly implemented, help deliver a validated facility on schedule, at the estimated cost, and with expected quality.

A new oral dosage product was designed as "encapsulated tablets." In production, the drug product was pressed into tablets, which were then fed into a revolving capsule-filling table.

If judges and juries lack the scientific knowledge to decide drugsafety cases, how can we protect both companies and patients?

CDER is reorganizing staffs and developing new policies to encourage industry adoption of quality production systems.

Roche (Basel, Switzerland, www.roche.com) has put a temporary halt on the distribution of the antiviral treatment, "Tamiflu" (oseltamivir phosphate), a neuraminidase inhibitor, to the United States in an effort to deter companies from stockpiling the antiviral for employee use, according to an article in the Oct. 27 edition of The New York Times.

Pharmaceutical Technology Europe
Particle shape is an important parameter to monitor in the pharmaceutical sector, but has, historically, been too complicated to measure and be utilized on a routine basis. A newly developed digital technique could change this.

Pharmaceutical Technology Europe
In applying a visually clean standard, any residue related to the cleaning process that is visible on the surface should constitute a failure.

Pharmaceutical Technology Europe
A new Good Automated Manufacturing Practice (GAMP) guide on IT Infrastructure Control & Compliance was launched in Chicago (IL, USA) 23 August 2005.1 The guide is intended to support pharmaceutical companies in their effort to establish a well-defined and compliant infrastructure. This article discusses different aspects of the guide that may support your organization in getting — and keeping — your infrastructure under control.

Pharmaceutical Technology Europe
Exploring a simple and systematic approach to validating an FMS.

ePT--the Electronic Newsletter of Pharmaceutical Technology
OTC Eye-Drop Maker Signs Consent Decree

ePT--the Electronic Newsletter of Pharmaceutical Technology
American Pharmaceutical Partners to Merge with American BioScience

ePT--the Electronic Newsletter of Pharmaceutical Technology
This week, the US Food and Drug Administration posted an Oct. 20 Warning Letter (http://www.fda.gov/foi/warning_letters/g5567d.htm) sent by its Minneapolis, MN district office to Diversified Manufacturing Corporation (Newport, MN).

ePT--the Electronic Newsletter of Pharmaceutical Technology
CDER 2005 Product Approval Totals Proposed CDER Reorganization

ePT--the Electronic Newsletter of Pharmaceutical Technology
The International Organization for Standardization (ISO, www.iso.org) has approved the use of the photometric method for liquid delivery performance verification. Artel (Westbrook, ME, www.artel-usa.com), a manufacturer of precision testing and calibration systems for liquid handling instruments, uses the photometric method to calibrate pipettes and automated liquid handlers.

ePT--the Electronic Newsletter of Pharmaceutical Technology
11 Universities Join FDA ?National Institute for Pharmaceutical Technology and Education?

New FDA Guidance on Electronic Common Technical Document Submissions

US District Court Rejects FDA Suit to Block Device Manufacturer

"It was just after FDA had initiated the Pre-Approval Inspection process," reports our GMP Agent-in-Place.

New leadership must address political and scientific issues as the Medicare drug benefit alters manufacturer incentives.

Moheb Nasr, PhD, director of the newly created Office of New Drug Quality Assessment at the US Food and Drug Administration (Rockville, MD, www.fda.gov), has proposed creating a "regulatory agreement" between FDA and sponsors to govern the chemistry, manufacturing, and controls (CMC) sections of new drug applications (NDAs).

This article provides a PhRMA perspective and recommendations on an FDA guidance currently under development dealing with postapproval changes after the final intermediate of the active pharmaceutical ingredient, i.e., BACPAC II. The concept of a "last true solution" is proposed as an additional point in the assessment of potential risk associated with process changes.

The extensible markup language (XML) format facilitates compliance with FDA's new requirements for prescription drug labeling submissions, improves patient safety, and enhances manufacturing sponsor efficiencies.

Information technology can streamline compliance and increase operational efficiency and quality.